Paris-based ophthalmics specialist Nicox has outlicensed rights to develop and sell Zerviate (cetirizine) to Samil Pharmaceutical, for the treatment of ocular itching associated with allergic conjunctivitis, in South Korea. 6 December 2019
Companies that manufacture ranitidine and nizatidine have been told to include all lots for N-nitrosodimethylamine (NDMA) before making them available to consumers. 5 December 2019
Alphamab Oncology, a China-based company developing eight bispecifics for cancer, plans to stage an IPO before the end of the year, according to a ChinaBio Today report. 4 December 2019
The US Food and Drug Administration has granted Breakthrough Therapy Designation for Orencia (abatacept) for the prevention of moderate to severe acute graft-versus-host disease (GvHD) in hematopoietic stem cell transplants from unrelated donors. 4 December 2019
Shionogi has launched Vyvanse (lisdexamfetamine dimesylate) 20mg/30mg capsules for use by children with attention deficit hyperactivity disorder (ADHD) in Japan. 3 December 2019
Specialised Therapeutics Asia (STA) has received approval to market Puma Biotechnology’s breast cancer drug Nerlynx (neratinib) in Singapore. 3 December 2019
Germany’s BioMed X has reached a milestone in its ongoing work with Boehringer Ingelheim, completing a project targeting chronic and disabling lung diseases. 2 December 2019
The Association of the British Pharmaceutical Industry (ABPI) has appointed Dr Richard Torbett as its new chief executive from January 1, 2020. 2 December 2019
Sweden’s Alligator Bioscience has appointed Malin Carlsson as chief operating officer. Dr Carlsson was formerly VP and head of translational medicine at Ferring Pharmaceuticals in Copenhagen. 29 November 2019
The European Commission has approved, under the EU Merger Regulation, the acquisition of Cambrex Corp of the USA by Permira Holdings of the UK. 28 November 2019
Shares in cancer-focused Norwegian biotech PCI Biotech have risen by more than 20% this week with news that the company’s pre-clinical research collaboration with Anglo-Swedish pharma major AstraZeneca has been extended. 28 November 2019
German gene therapy company ViGeneron has closed a series A funding round, raising an undisclosed amount from WuXi AppTec and Sequoia Capital China, among others. 28 November 2019
Osaka-based Ono Pharmaceutical has filed for Japanese approval for tirabrutinib, also known as ONO-4059, for people with Waldenstrom macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LPL). 27 November 2019
Hoth Therapeutics has entered into a licensing agreement to study North Carolina State University’s “exon skipping approach” for treating allergic diseases. 27 November 2019
US pharma giant Merck & Co’s mega-blockbuster anti-PD-1 therapy Keytruda (pembrolizumab) has been approved by the National Medical Products Administration (NMPA) in China in combination with carboplatin and paclitaxel for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). 26 November 2019
Pharma company and service partner Inceptua has become the exclusive distributor of products from German oncology generics manufacturer Bendalis, for their use in clinical trials worldwide. 25 November 2019
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
The European Medicines Agency’s pharmacovigilance committee, PRAC, has started a review of medicines containing finasteride and dutasteride following concerns regarding suicidal ideation (suicidal thoughts) and behaviors. 4 October 2024
Opioid Use Disorder (OUD) is a chronic neurological disorder that is described as the consequences associated with repeated, compulsive use of opioid drugs and prolonged self-administration of opioid drugs. 4 October 2024
Proposals from the National Health Service (NHS) England have been set out for a phased launch of Eli Lilly’s obesity injection Mounjaro/Zepbound (tirzepatide) at the start of a consultation. 4 October 2024
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
The US Food and Drug Administration (FDA) has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. 3 October 2024
Israel’s Teva Pharmaceutical Industries and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, have announced a global licensing deal for the development of an anti PD-1 oncology biosimilar candidate. 3 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024